<DOC>
	<DOCNO>NCT00001906</DOCNO>
	<brief_summary>While vaccination cutaneous leishmaniasis , chronic ulcerating protozoan infection skin , possible decade use live parasite , production storage live culture difficult . Since inoculation occasionally lead severe infection , expert advocate use . We show excellent protection use `` heat-killed '' vaccine combine autoclave leishmania antigen recombinant human interleukin-12 ( rhIL-12 ) aluminum hydroxide gel adjuvant rhesus macaque model disease . To assess safety immunogenicity vaccine human , propose rhIL-12 dose escalation Phase I/II trial .</brief_summary>
	<brief_title>Safety Immunogenicity Vaccine Cutaneous Leishmaniasis Using Recombinant Human Interleukin-12 Aluminum Hydroxide Gel Adjuvants</brief_title>
	<detailed_description>While vaccination cutaneous leishmaniasis , chronic ulcerating protozoan infection skin , possible decade use live parasite , production storage live culture difficult . Since inoculation occasionally lead severe infection , expert advocate use . We show excellent protection use `` heat-killed '' vaccine combine autoclave leishmania antigen recombinant human interleukin-12 ( rhIL-12 ) aluminum hydroxide gel adjuvant rhesus macaque model disease . To assess safety immunogenicity vaccine human , propose rhIL-12 dose escalation Phase I/II trial .</detailed_description>
	<mesh_term>Leishmaniasis</mesh_term>
	<mesh_term>Leishmaniasis , Cutaneous</mesh_term>
	<mesh_term>Aluminum Hydroxide</mesh_term>
	<mesh_term>Interleukin-12</mesh_term>
	<criteria>Male nonpregnant female 18 50 year age time screen willing use effective birth control one month post vaccination . Free obvious health problem establish medical history clinical examination enter study . Available participate duration study ( approximately 6 month ) . Able give sign informed consent . May receive investigational leishmania vaccine skin test , recombinant human interleukin12 . No use investigational drug vaccine study vaccine within 30 day precede dose , plan use study period . No administration chronic immunosuppressant ( define 14 day ) immunemodifying drug within six month vaccination . ( For corticosteroid , mean prednisone , equivalent , great 0.5 mg/kg/day . Inhaled topical steroid allow . ) No history prior leishmaniasis extensive travel region endemic leishmaniasis , southern Mexico , Central South America , Mediterranean region Middle East , Africa , India . No confirm suspect immunosuppressive immunodeficient condition , include human immunodeficiency virus ( HIV ) infection . No family history congenital hereditary immunodeficiency . No history significant allergic disease reaction likely exacerbate component . No acute disease time enrollment , define presence moderate severe illness without fever . No acute chronic , clinically significant pulmonary , cardiovascular , hepatic renal function abnormality , determine physical examination laboratory screen test . No pregnant lactating female . Must suspect known alcohol drug abuse . No significant finding , opinion investigator , would increase risk adverse outcome participate study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2000</verification_date>
	<keyword>Alum</keyword>
	<keyword>Antigen</keyword>
	<keyword>Cytokine</keyword>
	<keyword>Parasitic Infection</keyword>
	<keyword>Phase I</keyword>
	<keyword>Cutaneous Leishmaniasis</keyword>
</DOC>